Document is current

Any future updates will be listed below

Correction to: Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms

Crossref DOI link: https://doi.org/10.1007/s40121-022-00660-6

Published Online: 2022-06-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark